Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obefazimod - Abivax

Next Previous
X
Search
Drug Profile

Obefazimod - Abivax

Alternative Names: ABX-464; SPL-464

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Splicos
  • Developer Abivax
  • Class Amines; Anti-inflammatories; Antirheumatics; Antivirals; Chlorobenzenes; Fluorobenzenes; Quinolines; Small molecules
  • Mechanism of Action MiRNA-124 expression stimulants; RNA cap-binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase II/III COVID 2019 infections
  • Phase II Rheumatoid arthritis
  • Phase I Crohn's disease
  • Discontinued HIV infections

Most Recent Events

  • 29 Jul 2024 Abivax withdraw phase IIb/III trial prior to enrolment in Crohn's disease in Belgium (PO) (NCT03905109)
  • 15 Jul 2024 Abivax anticipates submission of an NDA to the US FDA in ulcerative colitis in late H1 2026
  • 11 Jul 2024 Abivax anticipates supplemental New Drug Application (sNDA) submission in Crohn's disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top